Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81047 | 1.00 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL8377208 | 1.00 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL7519633 | 1.00 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL8379909 | 1.00 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL5267200 | 1.00 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL6566958 | 0.98 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL394098 | 0.98 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| Hydrochloric Acid SCHEMBL5267197 | 0.98 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL27285973 | 0.98 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL168311 | 0.98 | NAAA (0.61) | NAAAEPHX1FAAHRAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216036-B1 | TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES | ALZA CORP (US) | 2005-11-16 | — | — | EP | claimed |
| US-6960353-B2 | Formulations for the transdermal administration of fenoldopam | ALZA CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040258742-A1 | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines | VAN OSDOL WILLIAM WOODSON (US) | 2004-12-23 | — | — | US | claimed |
| EP-1100476-B1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORP (US) | 2004-06-16 | — | — | EP | claimed |
| US-20040057987-A1 | Novel formulations for the transdermal administration of fenoldopam | VAN OSDOL WILLIAM W (US) | 2004-03-25 | — | — | US | claimed |
| US-6699497-B1 | PERMEATION ENHANCER | ALZA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-20030198662-A1 | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines | VAN OSDOL WILLIAM WOODSON (US) | 2003-10-23 | — | — | US | claimed |
| EP-1216036-A1 | TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES | Alza Corporation (US) | 2002-06-26 | — | — | EP | claimed |
| EP-1100476-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2001019352-A1 | TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES | ALZA CORPORATION (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000004886-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2000-02-03 | — | — | WO | claimed |
| EP-4736873-A1 | ANTI-IL-4RALPHA ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250257116-A1 | ANTI-CLEAVAGE MUTANT OF CD16 FOR ENHANCING CELL FUNCTION | NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| CN-119968452-A | Perfume mixture (VI) | 西姆莱斯股份公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250134934-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | REGENX SCIENCE, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| EP-1169025-A2 | TRANSDERMAL DRUG DELIVERY DEVICES COMPRISING A POLYURETHANE DRUG RESERVOIR | Alza Corporation (US) | 2002-01-09 | — | — | EP | disclosed |
| EP-1100476-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001019352-A1 | TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES | ALZA CORPORATION (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000059483-A2 | TRANSDERMAL DRUG DELIVERY DEVICES COMPRISING A POLYURETHANE DRUG RESERVOIR | ALZA CORPORATION (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000004886-A1 | FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM | ALZA CORPORATION (US) | 2000-02-03 | — | — | WO | disclosed |